Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals

Current Opinion in HIV and AIDS

Volumn 9, Issue 1, 2014, Pages 63-71

  Achhra, Amit C ^a   Petoumenos, Kathy ^a   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

AIDS; cancer; cardiovascular; CD4 cell count; CD4 cell count slope; HAART; hepatic; HIV; monitoring; mortality; non AIDS

Indexed keywords

CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; LIVER DISEASES; NEOPLASMS;

EID: 84892364090     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000017     Document Type: Review

References (54)

1. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14: 195-207
2. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIVinfected persons: The Swiss HIV cohort study. Clin Infect Dis 2011; 53: 1130-1139
3. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010; 376: 49-62
4. Lodwick RK, Sabin CA, Porter K, et al., Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: A pooled cohort observational study. Lancet 2010; 376: 340-345
5. Lewden C, Gabillard D, Minga A, et al. CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa. JAIDS 2012; 59: 213-219
6. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012; 54: 714-723
7. Bassett IV, Sax PE. Untreated HIV: Harmful even at high CD4 cell counts. Lancet 2010; 376: 306-308
8. Rasmussen LD, Engsig FN, Christensen H, et al. Risk of cerebrovascular events in persons with and without HIV: A Danish nationwide populationbased cohort study. AIDS 2011; 25: 1637-1646
9. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-622
10. Lewden C, Bouteloup V, De Wit S, et al., Collaboration of Observational HIVEREiE. All-cause mortality in treated HIV-infected adults with CD4-500/ mm3 compared with the general population: Evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41: 433-445
11. Lundgren JD, Babiker A, El-Sadr W, et al., Strategies for Management of Antiretroviral Therapy Study Group. Inferior clinical outcome of the CD4 cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4 cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197: 1145-1155
12. Hoffmann CJ, Schomaker M, Fox MP, et al. CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: Multicohort analysis from South Africa. J Acquir Immune Defic Syndr 2013; 63: 34-41
13. Mocroft A, Phillips AN, Gatell J, et al. CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS 2013; 27: 907-918
14. Masiá M, Padilla S, Á lvarez D, et al. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: Role of antiretroviral therapy. AIDS 2013; 27: 181-189
15. Zhang S, van Sighem A, Kesselring A, et al. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy. JAIDS 2012; 60: 265-272
16. van Lelyveld SF, Gras L, Kesselring A, et al. Long-Term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS 2012; 26: 465-474
17. Reekie J, Gatell JM, Yust I, et al. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS 2011; 25: 2259-2268
18. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010; 24: 1877-1886
19. Lucero C, Torres B, Leon A, et al. Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm3. AIDS Res Hum Retroviruses 2013; 29: 1161-1167
20. Young J, Psichoqiou M, Meyer L, The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 cell count and the risk of AIDS or death in HIVInfected adults on combination antiretroviral therapy with a suppressed viral load: A longitudinal cohort study from COHERE. PLoS Med 2012; 9: E1001194
21. Wolbers M, Babiker A, Sabin C, et al. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy-The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. PLoS Med 2010; 7: E1000239
22. Bray S, Gedeon J, Hadi A, et al. Predictive value of CD4 cell count nadir on long-Term mortality in HIV-positive patients in Uganda. HIV/AIDS 2012; 4: 135-140
23. Helleberg M, Kronborg G, Larsen CS, et al. CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV. Clin Infect Dis 2013; 57: 314-321
24. Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010; 116: 5507-5516
25. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS 2012; 26: 1017-1025
26. Krishnan S, Schouten JT, Jacobson DL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: An ACTG longitudinal linked randomized trials analysis. Oncology 2011; 80: 42-49
27. Petoumenos K, van Leuwen MT, Vajdic CM, et al. Cancer, immunodeficiency and antiretroviral treatment: Results from the Australian HIV Observational Database (AHOD). HIV Med 2013; 14: 77-84
28. Prosperi MC, Cozzi-Lepri A, Castagna A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: Evidence from a large Italian cohort study. Clin Infect Dis 2010; 50: 1316-1321
29. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and nonacquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116: 5306-5315
30. Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011; 52: 1458-1465
31. Vogel M, Friedrich O, Luchters G, et al. Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence. Eur J Med Res 2011; 16: 101-107
32. Calabresi A, Ferraresi A, Festa A, et al. Incidence of AIDS-defining cancers and virus-related and nonvirus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999-2009. HIV Med 2013; 14: 481-491
33. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol 2009; 10: 1152-1159
34. Sabin CA, Ryom L, De Wit S, et al. Associations between immune depression and cardiovascular events in HIV infection. AIDS 2013. [Epub ahead of print]
35. Vinikoor MJ, Napravnik S, Floris-Moore M, et al. Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. AIDS Res Hum Retroviruses 2013; 29: 1068-1074
36. Chow FC, Regan S, Feske S, et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US healthcare system. J Acquir Immune Defic Syndr 2012; 60: 351-358
37. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4 T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51: 435-447
38. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. JAIDS 2010; 55: 615-619
39. d'Arminio A, Sabin CA, Phillips AN, et al., The Writing Committee for the D: A: D Study Group. Cardio-And cerebrovascular events in HIV-infected, persons. AIDS 2004; 18: 1811-1817
40. Crane H, Paramsothy P, Heckbert S, et al. Primary vs. secondary MI events among HIV individuals: The CNICS cohort. Poster 821. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, USA; 2012
41. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 353-367
42. Smith C, Sabin CA, Lundgren JD, Data Collection on Adverse Events of Anti HIVdSG. Factors associated with specific causes of death amongst HIVpositive individuals in the D: A: D Study. [Erratum appears in AIDS. 2011 Mar 27;25(6): 883 Note: Multiple author names added]. AIDS 2010; 24: 1537-1548
43. Kovari H, Sabin CA, Ledergerber B, et al. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: The data collection on adverse events of anti-HIV drugs study. Clin Infect Dis 2013; 56: 870-879
44. Towner WJ, Xu L, Leyden WA, et al. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. JAIDS 2012; 60: 321-327
45. Sax PE. Editorial commentary: Can we break the habit of routine CD4 monitoring in HIV care? Clin Infect Dis 2013; 56: 1344-1346
46. Gale HB, Gitterman SR, Hoffman HJ, et al. Is frequent CD4 T-lymphocyte count monitoring necessary for persons with counts -300 cells/ml and HIV-1 suppressioñClin Infect Dis 2013; 56: 1340-1343
47. Girard P-Ma, Nelson Mb, Mohammed P, et al. Can we stop CD4 testing in patients with HIV-1 RNA suppression on antiretroviral treatment? Analysis of the ARTEMIS trial. AIDS 2013. [Epub ahead of print
48. Byakwaga H, Kelly M, Purcell DFJ, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 T-cell response: A randomized controlled trial. J Infect Dis 2011; 204: 1532-1540
49. Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: Results from the D: A: D study-. HIV Med 2011; 12: 412-421
50. Achhra AC, Amin J, Sabin C, et al. Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. AIDS 2012; 26: 1707-1717
51. Rotger M, Glass TR, Junier T, et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis 2013; 57: 112-121
52. Lundgren J, Babiker A, Gordin F, et al. When to start antiretroviral therapy: The need for an evidence base during early HIV infection. BMC Med 2013; 11: 148
53. Babiker AG, Emery S, Fätkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of Antiretroviral Treatment (START) study. Clin Trials 2013; 10: S5-S36
54. Wright ST, Carr A, Woolley I, et al. CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts. JAIDS 2011; 58: 72-79